Nippon India Pharma Fund-Growth Plan-Growth Option
Category: Equity: Sectoral-Pharma and Healthcare
Launch Date: 01-06-2004
AUM:
₹ 8,113.59 Cr
Expense Ratio
1.82%
Benchmark
BSE Healthcare TRI
ISIN
INF204K01968
Minimum Investment
5000.0
Minimum Topup
1000.0
Minimum SIP Amount
100
Fund Manager
Sailesh Raj Bhan
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Nippon India Pharma Fund-Growth Plan-Growth Option | 1.27 | 21.85 | 17.99 |
| Benchmark | - | - | - |
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
If you invested in this fund:
In the past (time duration):
Total value today:
0
Returns:
0%
Overview
NAV
514.0168
Last change
-2 (-0.3894%)
Fund Size (AUM)
₹ 8,113.59 Cr
Performance
20.21% (Inception)
Asset Allocation
Equity
Debt
Others
Nav Movement
Investment Objective
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. There is no assurance that the investment objective of the Scheme will be achieved.
Fund Manager
Sailesh Raj Bhan
Riskometer
Very High
Top 10 Holdings
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 12.29 |
| LUPIN LIMITED EQ NEW F.V. RS.2/- | 7.26 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 7.01 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 6.48 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 5.92 |
| Dr. Reddys Laboratories Ltd | 5.91 |
| VIJAYA DIAGNOSTIC CENTRE LIMITED EQ NEW FV Re.1/- | 3.56 |
| MEDPLUS HEALTH SERVICES LIMITED EQ NEW FV RS.2/- | 3.39 |
| GLAND PHARMA LIMITED EQ NEW FV Re.1/- | 3.24 |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD EQ | 2.99 |
Sector Allocation
| Sector | Holdings (%) |
|---|---|
| Healthcare | 96.05 |
| Consumer Services | 3.39 |